INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE EVIDENCE INDEX

The Study Library.

8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.

Showing studies that examined tomatoes. Clear

An expert overview of the literature, useful as background reading.

3 studies

2019 / Narrative review

Nutraceuticals, medicinal plants, and antioxidant-rich diets show potential roles in managing or preventing benign and malignant prostate diseases.

This review summarizes evidence for nutraceuticals and medicinal plants in treating and preventing prostate diseases. Epidemiological studies link the Mediterranean diet, high fruit and vegetable consumption, lycopene, and zinc with protection against prostate cancer or benign prostatic hyperplasia (BPH). Meta-analyses indicate Serenoa repens is more effective than placebo for mild to moderate lower urinary tract symptoms, while agents like lycopene, selenium, pollen extract, and beta-sitosterol also demonstrate symptomatic improvements in BPH or chronic pelvic pain syndrome.

Cicero AFG, Allkanjari O, Busetto GM, et al. Arch Ital Urol Androl, 2019. PMID 31577095

2009 / Narrative review

Review summarizes evidence linking vegetable intake and bioactive compounds to prostate cancer risk.

This review summarizes epidemiological evidence on vegetable intake, bioactive compounds, and prostate cancer risk. Accumulating evidence supports the consumption of lycopene, particularly tomato and tomato-based products, as protective factors against prostate cancer. Evidence for beta-carotene is inconsistent, whereas data on pulses or soy are limited but suggestive of decreased risk. Limited evidence leaves the roles of vitamin C, vitamin E, allium vegetables, and cruciferous vegetables on prostate cancer risk undetermined.

Shows an association, not proof of cause and effect.

Chan R, Lok K, Woo J Mol Nutr Food Res, 2009. PMID 19065589

2007 / Evidence-based regulatory review

FDA found no credible evidence for lycopene and cancer reduction, and only very limited evidence linking tomato intake to reduced risks of four cancers.

The U.S. FDA evaluated scientific evidence submitted in petitions for qualified health claims regarding tomato and lycopene consumption and cancer risk. The agency found no credible evidence to support an association between lycopene intake and reduced risk of prostate, lung, colorectal, gastric, breast, ovarian, endometrial, or pancreatic cancer. Additionally, no credible evidence supported an association between tomato consumption and reduced risk of lung, colorectal, breast, cervical, or endometrial cancer. The FDA identified only very limited evidence supporting an association between tomato consumption and reduced risks of prostate, ovarian, gastric, and pancreatic cancers.

Shows an association, not proof of cause and effect.

Kavanaugh CJ, Trumbo PR, Ellwood KC J Natl Cancer Inst, 2007. PMID 17623802